Boots CEO announces mole screening service
(09.02.17)

| News

Pharmacies could do much more than they do today says CEO of Boots.  Sarsia Seed portfolio company Screen Cancer is at the core of this strategy.

‘Pharmacies could do much more than what they do today,’ says Stefano Pessina the CEO of the mighty Walgreens Boots Alliance with a revenue of USD 103 billion and 370 000 employees. ‘Think of how much they could do as, let’s say, a port of first call.’

Stefano Pessina believes Boots can help take the strain off the creaking National Health Service.  A mole-screening trial will launch in March in 50 stores in partnerships with Screen Cancer.  It costs £42 for up to two moles. They will take a picture, send it off for analysis and then in a day or two tell the patient whether further checks are needed.

The early stage venture fund Sarsia Seed was one of the first investors in ScreenCancer in 2008.  Screen Cancer is part of the Pharma end E-Health portfolio of Sarsia Seed. Read more

Sarsia Seed